May 18, 2020 / 7:50 PM / 7 days ago

BRIEF-FDA Approves Genentech’S Tecentriq As A First-Line Monotherapy For Certain People With Metastatic Non-Small Cell Lung Cancer

May 18 (Reuters) - GENENTECH:

* FDA APPROVES GENENTECH’S TECENTRIQ AS A FIRST-LINE MONOTHERAPY FOR CERTAIN PEOPLE WITH METASTATIC NON-SMALL CELL LUNG CANCER

* GENENTECH - FDA APPROVAL BASED ON PHASE III IMPOWER110 STUDY ON TECENTRIQ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below